These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3479195)

  • 21. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions.
    Brand A; Claas FH; Voogt PJ; Wasser MN; Eernisse JG
    Vox Sang; 1988; 54(3):160-6. PubMed ID: 3369136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody response in patients with acute nonlymphocytic leukemia.
    Schiffer CA; Lichtenfeld JL; Wiernik PH; Mardiney MR; Joseph JM
    Cancer; 1976 May; 37(5):2177-82. PubMed ID: 1260708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous platelet transfusion in alloimmunized patients with acute leukemia.
    Funke I; Wiesneth M; Koerner K; Cardoso M; Seifried E; Kubanek B; Heimpel H
    Ann Hematol; 1995 Oct; 71(4):169-73. PubMed ID: 7578522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
    Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
    Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates.
    McFarland JG; Anderson AJ; Slichter SJ
    Br J Haematol; 1989 Nov; 73(3):380-6. PubMed ID: 2605125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of 'split' plateletpheresis products for alloimmunized patients.
    Gharpure VS; Norris D; Lee EJ; Schiffer CA
    Vox Sang; 1994; 67(3):272-4. PubMed ID: 7863627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alloimmunization following platelet transfusion: the absence of a dose-response relationship.
    Dutcher JP; Schiffer CA; Aisner J; Wiernik PH
    Blood; 1981 Mar; 57(3):395-8. PubMed ID: 7459428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serious adverse events after HPA-incompatible platelet transfusions in an alloimmunized patient with leukaemia.
    Sirén MK; Koponen A; Kekomäki R
    Transfus Med; 1998 Sep; 8(3):221-4. PubMed ID: 9800295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates.
    O'Connell BA; Lee EJ; Rothko K; Hussein MA; Schiffer CA
    Blood; 1992 Jan; 79(2):527-31. PubMed ID: 1730095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. The use of platelet transfusions.
    Feusner J
    Am J Pediatr Hematol Oncol; 1984; 6(3):255-60. PubMed ID: 6393789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between donor-recipient lymphocytotoxicity and the transfusion response using HLA-matched platelet concentrates.
    Herzig RH; Terasaki PI; Trapani RJ; Herzig GP; Graw RG
    Transfusion; 1977; 17(6):657-61. PubMed ID: 595123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet crossmatching with lymphocytotoxicity test: an effective method in alloimmunized Chinese patients.
    Chow MP; Yung CH; Hu HY; Tzeng JL; Lin WM; Lin CK
    Transfusion; 1991 Sep; 31(7):595-9. PubMed ID: 1891789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation.
    Semple JW; Speck ER; Milev YP; Blanchette V; Freedman J
    Blood; 1995 Jul; 86(2):805-12. PubMed ID: 7606011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-mediated inhibition of the human alloimmune response to platelet transfusion in Hu-PBL-SCID mice.
    Crow AR; Freedman J; Hannach B; Blanchette V; Lazarus AH
    Br J Haematol; 1999 Mar; 104(4):919-24. PubMed ID: 10192460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH
    Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of lymphocytotoxic antibody and antiplatelet antibody following blood transfusion and their clinical significance in platelet transfusion (author's transpl)].
    Deura K; Shimoyama M; Minato K; Kimura K; Shibata Y; Juji T
    Rinsho Ketsueki; 1978 Apr; 19(4):323-30. PubMed ID: 702815
    [No Abstract]   [Full Text] [Related]  

  • 37. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
    Toor AA; Choo SY; Little JA
    Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
    Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD
    JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions.
    Fisher M; Chapman JR; Ting A; Morris PJ
    Vox Sang; 1985; 49(5):331-5. PubMed ID: 3909636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of lymphocytotoxic and platelet reactive antibodies: a prospective study in patients with acute leukaemia.
    Pamphilon DH; Farrell DH; Donaldson C; Raymond PA; Brady CA; Bradley BA
    Vox Sang; 1989; 57(3):177-81. PubMed ID: 2617951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.